Physician profile
Jon Peters
NPI 1689776106
$13,373.61
in general payments reported to CMS, 2019-2025
43 companies · $2,755 in 2025
The $2,755 reported for 2025 was more than what 96% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $4,750 · 2020: $800 · 2021: $600 · 2022: $602 · 2023: $1,340 · 2024: $2,527 · 2025: $2,755.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,622.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,622.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $3,703.05 | 2019-2025 | |
| Abbvie INC. | $2,165.69 | 2021-2025 | |
| Lundbeck LLC | $723.88 | 2022-2025 | Vyepti, Rexulti |
| Supernus Pharmaceuticals, INC. | $703.56 | 2019-2022 | |
| Pfizer INC. | $667.73 | 2019-2025 | |
| Lilly USA, LLC | $544.53 | 2019-2025 | Kisunla, Amyvid, Emgality |
| Teva Pharmaceuticals USA, INC. | $509.87 | 2019-2025 | Ajovy, Austedo Xr |
| Argenx US, INC. | $391.47 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Biogen, INC. | $363.55 | 2019-2025 | Leqembi, Vumerity, Tysabri |
| Ucb, INC. | $339.36 | 2019-2024 | Rystiggo, Nayzilam, Briviact |
| Allergan, INC. | $335.07 | 2019-2022 | |
| Celgene Corporation | $259.16 | 2023-2025 | Zeposia |
| Genzyme Corporation | $256.28 | 2019-2025 | |
| Eisai INC. | $246.93 | 2019-2025 | |
| Alexion Pharmaceuticals, INC. | $243.51 | 2019-2025 | Ultomiris |
Show all 43 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avanir Pharmaceuticals, INC. | $227.79 | 2019-2021 | |
| Amgen INC. | $200.30 | 2019-2025 | Uplizna, Aimovig |
| Acorda Therapeutics, INC | $144.66 | 2019-2022 | |
| Neurelis, INC. | $130.68 | 2024-2025 | Valtoco |
| Biohaven Pharmaceuticals, INC. | $111.54 | 2021 | |
| Axsome Therapeutics, INC. | $110.95 | 2025 | Symbravo |
| Takeda Pharmaceuticals U.S.A., INC. | $102.31 | 2020-2025 | Hyqvia |
| Vanda Pharmaceuticals INC. | $95.34 | 2025 | Ponvory |
| Emd Serono, INC. | $85.67 | 2019-2020 | |
| Csl Behring | $75.03 | 2019-2025 | Hizentra |
| Livanova USA, INC. | $71.29 | 2020-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Mdd US Operations, LLC | $63.09 | 2024 | Gocovri |
| Amneal Pharmaceuticals LLC | $60.29 | 2024-2025 | Crexont |
| Tg Therapeutics, INC. | $45.56 | 2024-2025 | |
| Avadel Cns Pharmaceuticals, LLC | $45.46 | 2024 | Lumryz |
| Genentech USA, INC. | $42.60 | 2024 | Ocrevus Zunovo, Ocrevus |
| Acadia Pharmaceuticals INC | $40.14 | 2019 | |
| Life Molecular Imaging LTD | $35.40 | 2025 | Neuraceq |
| Philips North America LLC | $32.03 | 2024-2025 | Ecc Solutions, (Ck4) Mcot |
| Currax Pharmaceuticals LLC | $28.28 | 2022-2023 | Onzetra Xsail, Contrave |
| Jazz Pharmaceuticals INC. | $28.21 | 2024 | |
| Corium, LLC | $27.42 | 2024 | Azstarys |
| Merz North America, INC. | $26.42 | 2019 | |
| Tonix Medicines, INC. | $20.72 | 2025 | Tonmya |
| Astrazeneca Pharmaceuticals LP | $18.89 | 2025 | Wainua |
| Assertio Therapeutics, INC. | $18.67 | 2019 | |
| Noven Therapeutics, LLC | $16.59 | 2024 | Xelstrym |
| Sumitomo Pharma America, INC. | $14.64 | 2024 | Aptiom |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Peters listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.